Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 1 source

Constitutive KIT activation

“All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).” (opens the source at this quote in a new tab)